Skip to content

Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease.

Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease: a Phase I Clinical Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05146583
Enrollment
60
Registered
2021-12-07
Start date
2021-11-01
Completion date
2023-06-01
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Disc Disease

Keywords

Sciatica, Lumbar Disc Herniation, Discectomy

Brief summary

Lumbar discectomy and injection of purified cellular bone marrow concentrate or lumbar discectomy only

Detailed description

In order to find a regenerative treatment for back pain from DDD, cell based therapies have become of increasing interest. Recent clinical studies have shown promising improvement in pain and disc hydration, thus indicating a regenerative effect. The use of mesenchymal stem cells for regeneration of degenerated connective tissue of mesenchymal origin has proven efficient in multiple recent studies. However, the acquisition of mesenchymal stem cells (MSC) is always an extensive procedure requiring either enzymatic or genetic manipulation of acquired tissues. Thus, the use of these MSCs is highly controversial and raises concerns in terms of patient safety. One of the most commonly used sources for MSCs is bone marrow tissue. Even when not manipulated, these tissues already contain a significant amount of mesenchymal stem cells and growth factors. Therefore, they are used for regenerative treatments of multiple degenerative musculoskeletal diseases. This is an exploratory pilot study which aims to compare patient outcomes between two treatments approaches for DDD that are currently being used in clinic. While micro- discectomy is the standard of care for DDD, micro-discectomies with autologous bone marrow cell injections have been used in clinic in the past year. The goal of this study is to determine if the bone marrow injection group is superior compared to the control group (state of the art micro-discectomies) in enhancing degenerative disc recovery and improving or preventing back pain.

Interventions

PROCEDUREAutologous bone marrow aspirate injected intradiscal after microdiscectomy

Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.

PROCEDUREDiscectomy only

Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).

Sponsors

New York Presbyterian Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female patients ≥18 years of age 2. Radiologically (MRI) confirmed diagnosis degenerative disc disease of the lumbar spine and/or lumbar disc herniation 3. Unresponsive to conservative/non-operative treatment for \>3 months 4. Psychosocial, mental and physical ability to understand and to adhere to this protocol, especially adhering to the visit schedule follow-ups, and observe treatment plan 5. Signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the trial study-related procedures

Exclusion criteria

1. Pregnant or breastfeeding patients 2. Active malignancy 3. Active chronic or acute infection 4. Autoimmune disorder that impacts the lumbar spine (Ankylosing spondylitis, lupus eg.) 5. Acute Episode or major mental illness 6. Major cognitive impairment causing to inability to understand informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in Numeric Rating for Back pain at 12 monthsBaseline, 3 months, 6 months, 12 months after surgery0 to 10 NRS

Secondary

MeasureTime frameDescription
Change in Oswestry Disability Index at 12 monthsBaseline, 3 months, 6 months, 12 months after surgery0 to 100 PROM to measure low back disfunction
Disc Height IndexBaseline and 12 months or longer folllow-up after surgeryMRI measurement
Pfirrman gradingBaseline and 12 months or longer folllow-up after surgeryMRI measurement
Change in NRS Leg painBaseline, 3 months, 6 months, 12 months after surgery0 to 10 NRS
ComplicationsContinrous monitoring during study during one year after surgeryInfections, reoperations, blood loss.

Countries

United States

Contacts

Primary ContactRoger Hartl, Prof.dr.
ermabell@cornell.edu.com(212) 821-0850
Backup ContactPravesh Gadjradj, MD
psg4001@med.cornell.edu(212) 821-0850

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026